Cure Everyone and Vaccinate the rest: The patient perspective on future hepatitis B treatment.

2021 ◽  
Author(s):  
Catherine Freeland ◽  
Rhea Racho ◽  
Maureen Kamischke ◽  
Kate Moraras ◽  
Evangeline Wang ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Patient Perspective ◽  
Hepatitis B Treatment

scholarly journals Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice

2014 ◽  
Vol 13 (3) ◽  
pp. 327-336 ◽  
Author(s):  
Ezequiel Ridruejo ◽  
Sebastián Marciano ◽  
Omar Galdame ◽  
María V. Reggiardo ◽  
Alberto E. Muñoz ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Clinical Practice ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Efficacy And Safety ◽  
Hepatitis B Treatment ◽  
Treatment Naïve

scholarly journals DNA-guided hepatitis B treatment, viral load is essential, but not sufficient

2009 ◽  
Vol 15 (4) ◽  
pp. 423 ◽  
Author(s):  
Rafael Bárcena Marugán ◽  
Silvia García Garzóno
Keyword(s):  
Viral Load ◽  
Hepatitis B ◽  
Hepatitis B Treatment

scholarly journals Na+-Taurocholate Co-Transporting Polypeptide (NTCP) in Livers, Function, Expression Regulation, and Potential in Hepatitis B Treatment

Livers ◽  
2021 ◽  
Vol 1 (4) ◽  
pp. 236-249
Author(s):  
Xiaoyu Zhao ◽  
Waqas Iqbal ◽  
Pingnan Sun ◽  
Xiaoling Zhou
Keyword(s):  
Hepatitis B ◽  
Hepatoma Cell ◽  
Sodium Taurocholate ◽  
Hbv Infection ◽  
Viral Receptor ◽  
Hepatitis D ◽  
Hepatoma Cell Lines ◽  
Chronic Hepatitis B Virus ◽  
Hepatitis B Treatment

Chronic hepatitis B virus (HBV) infection has become one of the leading causes of liver cirrhosis and hepatocellular carcinoma globally. The discovery of sodium taurocholate co-transporting polypeptide (NTCP), a solute carrier, as a key receptor for HBV and hepatitis D virus (HDV) has opened new avenues for HBV treatment. Additionally, it has led researchers to generate hepatoma cell lines (including HepG2-NTCP and Huh-7-NTCP) susceptible to HBV infection in vitro, hence, paving the way to develop and efficiently screen new and novel anti-HBV drugs. This review summarizes the history, function and critical findings regarding NTCP as a viral receptor for HBV/HDV, and it also discusses recently developed drugs targeting NTCP.

scholarly journals Achieving a Cure: The Next Frontier in Hepatitis B Treatment

Liver Cancer ◽  
2021 ◽  
pp. 109-126
Author(s):  
Tina Boortalary ◽  
Brianna Shinn ◽  
Dina Halegoua-DeMarzio ◽  
Hie-Won Hann
Keyword(s):  
Hepatitis B ◽  
Hepatitis B Treatment

scholarly journals Scleromyxedema (Arndt - Gottron Syndrome) Developing Under Tenofovir Treatment for Hepatitis B: Unique Presentation in a Bulgarian Patient!

2019 ◽  
Vol 7 (5) ◽  
pp. 782-785 ◽  
Author(s):  
Ivanka Temelkova ◽  
James Patterson ◽  
Georgi Tchernev
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Hepatitis Virus ◽  
Histological Study ◽  
Drug Induced ◽  
Systemic Involvement ◽  
First Case ◽  
The Face ◽  
Hepatitis B Treatment

BACKGROUND: Scleromyxedema, also referred to as the Arndt-Gottron (S-AG) syndrome or the systemic form of Lichen myxedematosus (LM), is a cutaneous mucinosis with a chronic course and high lethality from systemic involvement of other organs and systems. Interesting in several aspects is the association between scleromyxedema and viral hepatitis about: 1) hepatitis virus infection as a possible etiological factor for the development of scleromyxedema, 2) antiretroviral therapy for the treatment of hepatitis as a method of reversing scleromyxedema and 3) antiviral drugs as inducers of scleromyxedema. CASE REPORT: We present a 53-year old patient who for nine months had been on tenofovir disoproxil 245 mg (0-0-1) therapy for chronic hepatitis B. Three months after the start of antiviral therapy (i.e. for a period of 6 months), the patient observed swelling, itching and hardening of the skin on the face, ears and hands, which subsequently spread throughout the trunk. Subsequent histological study of a skin biopsy revealed changes of scleromyxedema at an advanced stage, though immunoelectrophoresis of serum and urine excluded the presence of paraproteinaemia or para proteinuria. Systemic antihistamine and topical corticosteroid therapy were instituted. Bone involvement with possible plasmacytoma was excluded, and a myelogram showed evidence of an erythroblastic reaction of bone marrow. CONCLUSION: We believe that drug-induced scleromyxedema is a rare but possible phenomenon. We describe the first case of tenofovir-induced scleromyxedema within the framework of chronic hepatitis B treatment.

scholarly journals Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study

2018 ◽  
Vol 24 (5) ◽  
pp. 464-468
Author(s):  
Mina Tadrous ◽  
Mayur Brahmania ◽  
Diana Martins ◽  
Sandra Knowles ◽  
Harry L. A. Janssen ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Treatment Patterns ◽  
Publicly Funded ◽  
Ecologic Study ◽  
Hepatitis B Treatment
Sign in / Sign up

Export Citation Format

Share Document